Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice

European Respiratory Journal

Volumn 37, Issue 1, 2011, Pages 72-78

  Lubamba, B ^a   Lebacq, J ^a   Reychler, G ^a   Marbaix, E ^a   Wallemacq, P ^a   Lebecque, P ^a   Leal, T ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cystic fibrosis; Inhalation; Nasal potential difference; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

CHLORIDE ION; SILDENAFIL; TADALAFIL; TRANSMEMBRANE CONDUCTANCE REGULATOR; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHLORIDE TRANSPORT; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; DRUG EFFICACY; IN VIVO STUDY; MOUSE; NEBULIZATION; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; SODIUM CONDUCTANCE;

ADMINISTRATION, INHALATION; ANIMALS; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HOMOZYGOTE; HUMANS; IMIDAZOLES; MICE; MICE, TRANSGENIC; NEBULIZERS AND VAPORIZERS; PHOSPHODIESTERASE 5 INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PIPERAZINES; PURINES; SULFONES; TIME FACTORS; TRIAZINES;

EID: 79251582480     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00013510     Document Type: Article

References (30)

1. Amen N, Silvis M, Bradbury NA. Endocytic trafficking of CFTR in health and disease. J Cyst Fibros 2007; 6: 1-14.
2. Dalby R, Suman J. Inhalation therapy: technological milestones in asthma treatment. Adv Drug Deliv Rev 2003; 55: 779-791.
3. Geller DE. Aerosol antibiotics in cystic fibrosis. Respir Care 2009; 54: 658-670.
4. Cystic Fibrosis Foundation. Drug Development Pipeline. www.cff.org/treatments/pipeline Date last accessed: September 2010. Date last updated: September 27, 2010.
5. Blount MA, Beasley A, Zoraghi R, et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 2004; 66: 144-152.
6. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000; 92: 1702-1712. (Pubitemid 30412491)
7. Lubamba B, Lecourt H, Lebacq J, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008; 177: 506-515.
8. Doggrell SA. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Expert Opin Pharmacother 2005; 6: 75-84.
9. Bartolome SD, Channick RN. Sildenafil for pulmonary arterial hypertension. Future Cardiol 2006; 2: 137-143.
10. van Doorninck JH, French PJ, Verbeek E, et al. A mouse model for the cystic fibrosis delta F508 mutation. EMBO J 1995; 14: 4403-4411.
11. Nicklas W, Baneux P, Boot R, et al. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 2002; 36: 20-42.
12. Legssyer R, Huaux F, Lebacq J, et al. Azithromycin reduces spontaneous and induced inflammation in F508del cystic fibrosis mice. Respir Res 2006; 7: 134.
13. Leal T, Lebacq J, Vanbinst R, et al. Successful protocol of anaesthesia for measuring transepithelial nasal potential difference in spontaneously breathing mice. Lab Anim 2006; 40: 43-52. (Pubitemid 43341082)
14. Lubamba B, Lebacq J, Lebecque P, et al. Airway delivery of low dose miglustat normalizes nasal potential differenece in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009; 179: 1022-1028.
15. Gizurarson S. Animal models for intranasal drug delivery studies. A review article. Acta Pharm Nord 1990; 2: 105-122.
16. Leal T, Lebacq J, Lebecque P, et al. Modified method to measure nasal potential differenece. Clin Chem Lab Med 2003; 41: 61-67.
17. Leal T, Fajac I, Wallace HL, et al. Airway ion transport impacts on disease presentation and severity in cystic fibrosis. Clin Biochem 2008; 41: 764-772.
18. Phalen RF, Mannix RC, Drew RT. Inhalation exposure methodology. Environ Health Perspect 1984; 56: 23-34.
19. Raeburn D, Underwood SL, Vilamil ME. Techniques for drug delivery to the airways, and the assessment of lung function in animal models. J Pharmacol Toxicol Methods 1992; 27: 143-159.
20. Cryan SA, Sivadas N, Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosa barrier. Adv Drug Deliv Rev 2007; 59: 1133-1151.
21. Grubb BR, Rogers TD, Boucher RC, et al. Ion transport across CF and normal murine olfactory and ciliated epithelium. Am J Physiol Cell Physiol 2009; 296: C1301-C1309.
22. Mery S, Gross EA, Joyner DR, et al. Nasal diagrams: a tool for recording the distribution of nasal lesions in rats and mice. Toxicol Pathol 1994; 22: 353-372.
23. Harkema JR, Carey SA, Wagner JG. The nose revisited: a brief review of the comparative structure, function, and toxicologic pathology of the nasal epithelium. Toxicol Pathol 2006; 34: 252-269.
24. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects F508del-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005; 60: 55-59.
25. Berry B, Altman P, Rowe J, et al. Comparison of pharmacokinetics of vardenafil administered using an ultrasonic nebulizer for inhalation versus a single 10-mg oral tablet. J Sex Med 2009; [Epub ahead of print DOI: 10.1111/j.1743-6109.2009.01403.x].
26. Montgomery GS, Sagel SD, Taylor AL, et al. Effects of sildenafil on pulmonary hypertension and exercise tolerance in severe cystic fibrosis-related lung disease. Pediatr Pulmonol 2006; 41: 383-385.
27. Ionescu AA, Ionescu AA, Payne N, et al. Subclinical right ventricular dysfunction in cystic fibrosis: a study using tissue Doppler echocardiography. Am J Respir Crit Care Med 2001; 163: 1212-1218.
28. Poschet J, Perkett E, Deretic V. Hyperacidification in cystic fibrosis: links with lung disease and new prospects for treatment. Trends Mol Med 2002; 8: 512-519.
29. Toward TJ, Smith N, Broadley KJ. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med 2004; 169: 227-234.
30. Poschet JF, Timmins GS, Taylor-Cousar JL, et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 293: L712-L719.